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The renin−angiotensin−aldosterone system (RAAS) plays 
a pivotal role in maintaining a neurohormonal imbalance 
that promotes heart failure (HF).1–5 Neurohormonal activa-
tion acts to modify cardiac structure and function, inducing 
both left ventricular (LV) hypertrophy and collagen net-
work remodeling,6 changes that increase cardiovascular 
morbidity and mortality.7
It is well known that drugs interfering with the RAAS 
attenuate or even reverse LV remodeling and improve prog-
nosis;8–10 aldosterone levels often remain elevated or even 
increase in these patients because of the well-known 
‘escape’ phenomenon.11,12 In addition to the other compo-
nents of the RAAS, aldosterone directly promotes LV over-
load, hypertrophy, tissue-mediated responses (increase in 
cytokines, adhesion molecules, and endothelial dysfunc-
tion), and myocardial fibrosis.13,14
The pathophysiological rationale for aldosterone block-
ade in the treatment of HF is supported by large-scale rand-
omized clinical trials demonstrating that anti-aldosterone 
agents, when added to optimal therapy, consistently reduce 
cardiovascular morbidity and mortality in patients with 
advanced HF (New York Heart Association (NYHA) class 
III and IV),15 in patients with systolic HF and mild symp-
toms (NYHA class II),16 and in those with systolic dysfunc-
tion and HF following acute myocardial infarction (AMI).17 
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Abstract
Introduction: Several studies have definitively shown the benefit of mineralocorticoid receptor antagonists (MRAs) 
in patients with heart failure (HF). However, very few prior studies examined the relationship between the timing of 
initiation of MRAs and prognosis. In addition, on this topic, there is no information regarding the specific population of 
patients suffering a first episode of decompensated congestive HF.
Methods: We studied a homogenous cohort of patients discharged alive from our hospital after a first episode of 
decompensated congestive HF, in order to clarify the association between time of aldosterone receptor antagonist 
(ARA) initiation (within the first 90 days after hospital discharge) and mortality. Our population was composed of a 
series of consecutive patients. All-cause mortality was compared between patients who initiated MRAs at discharge 
(early group) and those who initiated MRAs one month later and up to 90 days after discharge (delayed group). We used 
prescription time distribution matching to control for survival difference between groups.
Results: The early and delayed groups consisted of 365 and 320 patients, respectively. During the one-year follow-up, a 
significant difference in mortality was demonstrated between groups. Adjusted hazard ratios (HRs) for early versus delayed 
initiation were 1.72 (95% confidence interval (CI) 0.96 to 2.84) at six months, and 1.93 (95% CI 1.18 to 3.14) at one year.
Conclusions: Delay of MRA initiation up to 30 to 90 days after discharge implies a significant increase in mortality 
compared with MRA initiation at discharge, after a first episode of decompensate congestive HF.
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Current guidelines recommend, in fact, using mineralocor-
ticoid receptor antagonists (MRAs) for all symptomatic 
patients (NYHA class II–IV) on top of optimal therapy, 
including β-blockers and angiotensin-converting enzyme 
inhibitors (ACE-Is) or angiotensin receptor antagonists 
(ARBs).18,19
Only two studies examined the relationship between the 
timing of initiation of MRAs and prognosis. The first of 
these is the study by Adamopoulos et al.,20 who performed 
a preliminary exploratory analysis of the Eplerenone Post-
AMI Heart Failure Efficacy and Survival (EPHESUS) trial. 
This study demonstrated that an earlier aldosterone block-
ade improved outcome in patients with HF, and this benefit 
was not observed when the aldosterone receptor antagonist 
(ARA) was initiated later. The other study is by Hayashi et 
al.,21 who found that the treatment with MRAs within 24 
hours after an AMI may prevent post-infarct LV remode-
ling. However, there is no information concerning how the 
beneficial effect of aldosterone inhibition relates to the tim-
ing of MRA initiation in the specific population of patients 
suffering a first episode of decompensated congestive HF.
Using the database of our hospital, we selected a homog-
enous cohort of consecutive patients in order to study the 
association between time of MRA initiation (within the first 
90 days after hospital discharge) and mortality in patients 
with HF discharged alive after a first episode of decompen-
sated congestive HF. Risk of mortality was computed com-
paring patients who initiated MRAs at discharge (early 
group), who we postulate to be advantaged, and those who 




Eligible patients were residents of the Province of Modena, 
who were discharged alive from the Modena Policlinico 
Hospital after a first episode of decompensated congestive 
HF between January 2007 and March 2010. Follow-up data 
were available for these patients until April 2011.
“MRA users” (see definition below) who were dis-
charged alive from their first hospitalization for decompen-
sated congestive HF were included. Patients were excluded 
if they met ≥ one of the following conditions: (1) presence 
of severe comorbidities (significant renal impairment 
(defined as reduction of the glomerular filtration rate, cal-
culated by the Modification of Diet in Renal Disease equa-
tion, < 60 ml/min/1.73 m2), dementia, or malignancy); (2) 
age ≥ 85 years. These two groups of patients were frail and 
likely to have a short life expectancy, which may have 
obscured the effect of treatments; and (3) a total length of 
hospital stay ≤ three days.
Patients who filled a prescription of an MRA ≤ 90 days 
after discharge were identified as “MRA users.” Those who 
had a prescription dispensed at discharge formed the “early 
group,” and those who filled a prescription 30 to 90 days 
after discharge formed the “delayed group.”
The study outcome was defined as mortality due to any 
cause. All patients were followed for the earliest occur-
rence of death or one year after discharge.
Data source
Data were obtained from the general database of our hospi-
tal, which contains information concerning hospital admis-
sions, discharge reports, inpatient physician encounters, 
and dispensed medications. Prescription information 
includes type of medication and dispensed dose.
Death information was obtained from the Modena pro-
vincial registry office.
Detailed information on patients’ baseline characteris-
tics, including medication and doses, was recorded at dis-
charge (baseline).
Baseline characteristics
General information, including patients’ age, gender, and 
co-morbidity, was noted at discharge. Concurrent use of 
major cardiac medications was recorded for beta blockers, 
nitrates, diuretics, warfarin, digoxin, ACE-Is, ARBs, and 
MRAs. In addition, data included: date of cardiac proce-
dures after the index hospital admission (catheterization, 
percutaneous coronary intervention, or coronary artery 
bypass grafting), and length of hospital stay.
Prescription time distribution matching
By definition, patients in the delayed group survived at 
least the first month and up to 90 days, whereas patients in 
the early group may have had an event any time after dis-
charge. Although the risk of death is higher after discharge, 
an excessive amount of early events is expected to occur in 
the early group. This systematic difference in time to treat-
ment initiation may result in biased estimates if not cor-
rected for either at the design or analysis level. To address 
this between-group survival difference, we used the method 
of prescription time distribution matching to define time of 
study entry (T0). The method considered the dispensing 
date of the first MRA prescription (the date of post- 
discharge visit) was considered to be the time of study entry 
of the delayed users. Early users were assigned a T0 that 
was selected at random from the observed prescription time 
distribution of the delayed users. Those who died before the 
assigned T0 were excluded. The two groups were then fol-
lowed from their respective T0 values, and onward.
Statistical analyses
Descriptive statistics were used to compare baseline patient 
characteristics between groups.
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To exclude the possibility that the delayed users were 
late to fill the prescription because they underwent more 
post-discharge procedures or hospital readmissions, we 
examined the period between discharge and matched pre-
scription time for rates of cardiac procedures (percutaneous 
coronary intervention, coronary artery bypass grafting, and 
catheterization) and hospital admissions for congestive HF.
Survival in the two groups was displayed by a Kaplan–
Meier curve. A multivariate Cox’s regression model was 
used to obtain the hazard ratio (HR) of mortality between 
the delayed (reference) and early groups after adjusting for 
baseline characteristics. Mortality hazards were evaluated 
at six months and at one year after discharge.
A p < 0.05 was considered statistically significant.
Results
Cohort and baseline characteristics
In our cohort, 689 consecutive patients filled an MRA pre-
scription during the first 90 days after discharge. Of these, 
365 patients (52.6% of the entire population) filled an MRA 
prescription at discharge (early group), and 320 patients 
(47.4%) initiated an MRA 30 to 90 days after discharge 
(delayed group).
After matching on study entry between the early and 
delayed users, the early group had an assigned T0 distribu-
tion identical to that of the delayed users (median: 55 days; 
interquartile range: 40 to 72 years). There were four sub-
jects who were excluded from the early group because they 
died before their assigned T0.
A comparison between early and delayed users after pre-
scription time distribution matching showed similar demo-
graphic and clinical characteristics (Table 1). Also, as 
regards the type and dose of the prescribed drugs, we did 
not note any significant difference. Specifically, types and 
dose of prescribed MRAs are summarized in Table 2. 
Patients did not significantly differ in terms of types and 
dose of prescribed MRAs.
Treatment rates after discharge and up to 
matched prescription time
There was no difference in the rates of post-discharge cardiac 
procedures and hospital admissions up to matched T0 between 
the early and delayed groups. For post-discharge cardiac pro-
cedures, rates in the early and delayed groups were 9% and 
10%, respectively (p = 0.32). For post-discharge hospital 
admissions, rates were 6% and 7% (p = 0.26).
Effect associated with difference in timing of 
MRA initiation
Twenty-six patients in the early group (7.1%) and 43 in the 
delayed group (13.4%) died in the first year after first hospital 
admission. Kaplan–Meier curve (Figure 1) and multivariate 
Cox’s regression analysis showed a significant difference in 
mortality due to delay of MRA initiation.
Adjusted HRs for mortality for delayed versus early ini-
tiation were 1.72 (95% confidence interval: 0.96 to 2.84) at 
six months, and 1.93 (95% confidence interval: 1.18 to 3.14) 
at one year after discharge (comparison was controlled for 
survival bias by prescription time distribution matching).
Discussion
The present study evaluated the effectiveness of early MRA 
use compared with delayed initiation in a population of 
patients hospitalized for a first episode of decompensated 
HF. Compared with a delay in MRA initiation, early users 
show a significant difference in mortality compared with 
delayed users during the first year after discharge. Based on 
the survival curve, a delay of only one month in the admin-
istration of an MRA implies approximately a doubling of 
mortality risk after one year. This aspect may be important 
from a practical point of view, because even the most recent 
guidelines do not provide guidance regarding how early to 
start MRA treatment after hospitalization for congestive 
HF. The present study provides a clear indication for use of 
MRAs as early as possible, on top of the treatment (includ-
ing ACE-I or ARB and beta-blocker), preferably at dis-
charge after an episode of decompensate HF.
The reason to define delayed use as one month to 90 days 
in the present study is threefold. First, this is determined by 
the actual prescription pattern. The first 90-day period cap-
tured practically all the first MRA prescriptions in the year 
after discharge.22 Second, the highest risk of readmission 
and death occurs during the first month after discharge.23,24 
Third, the EPHESUS trial suggests that earlier eplerenone 
administration improved outcomes in patients with HF, that 
this benefit was not demonstrated when eplerenone was ini-
tiated later,20 and that the reduction in mortality from any 
cause was apparent within the first 30 days of randomiza-
tion.25 Therefore, it is important, in our opinion, to examine 
the effect on mortality as a result of an initiation delay ≥ one 
month compared with initiation at discharge.
Pathophysiological effects of aldosterone and 
“aldosterone escape” in congestive heart failure
Mineralocorticoid antagonism attenuates cardiovascular 
damage by mechanisms that involve direct blockade of 
aldosterone’s cardiovascular pro-inflammatory and pro-
fibrotic effects.26 Aldosterone induces fibrosis in the heart, 
blood vessels, and kidney,25 and the antagonism of miner-
alocorticoid receptors has been associated with reduced 
fibrosis in human myocardium, limited ventricular remod-
eling, and improved survival in patients with ventricular 
dysfunction and heart failure.14,25–28 Our results suggest a 
greater benefit in terms of survival if MRA treatment is 
started as early as possible.
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Table 1. Baseline (at discharge) characteristics of mineralocorticoid receptor antagonists users, discharged alive from a first 
episode of decompensated congestive heart failure.




Age, years 73 ± 13 72 ± 13
Men 55.0% (n = 201) 54.6% (n = 175)
Risk factors and baseline co-morbidities
BMI, kg/m2 27 ± 5 27 ± 6
Smoking history 53.4% (n = 195) 52.8% (n = 169)
Hypertension 39.7% (n = 145) 39.0% (n = 125)
Diabetes mellitus 17.8% (n = 65) 17.2% (n = 55)
Chronic atrial fibrillation 18.9% (n = 69) 18.1% (n = 58)
Hospital characteristics
Ischemic cause of HF 47.9% (n = 175) 46.9% (n = 150)
Systolic blood pressure at discharge, mm Hg 114 ± 18 115 ± 20
Left ventricular EF, % 35 ± 7 36 ± 7
Left ventricular EDD, mm 68 ± 10 67 ± 10
Severe mitral regurgitation 24.9% (n = 91) 25.0% (n = 80)
Serum sodium, mEq/l 137 ± 7 136 ± 8
Serum potassium, mEq/l 4.0 ± 0.4 3.9 ± 0.3
Blood urea nitrogen, mg/dl 33 ± 17 31 ± 20
Creatinine, mg/dl 1.2 ± 0.6 1.1 ± 0.9
Albumin, g/dl 3.9 ± 0.8 4.1 ± 1.0
Hemoglobin, g/dl 12.7 ± 3.8 13.0 ± 2.1
Total cholesterol, mg/dl 184 ± 64 175 ± 57
Length of hospital stay, days 8 (range: 5–16) 9 (range: 5–17)
Cardiac medicationsc
Furosemide 100% (n = 365) 100% (n = 320)
Furosemide prescribed dose at discharge, mg/die 43 ± 18 48 ± 20
ACE-I or ARB 100 % (n = 365) 100 % (n = 320)
Beta-blockers 81.9% (n = 299) 82.2% (n = 263)
Digoxin 9.6% (n = 35) 9.1% (n = 29)
Statin 50.7% (n = 185) 50.3% (n = 161)
Warfarin 21.9% (n = 80) 21.6% (n = 69)
Antiplatelet drugs 49.9% (n = 182) 50.3% (n = 161)
aUsers who initiated mineralocorticoid receptor antagonists at discharge; busers who filled an mineralocorticoid receptor antagonists prescription 30 
to 90 days after discharge; crates of cardiac medication use up to the matched time of first mineralocorticoid receptor antagonists prescription. BMI: 
body mass index; HF: heart failure; EF: ejection fraction; EDD: end-diastolic diameter; ACE-I: angiotensin-converting enzyme inhibitor; ARB: angiotensin 
receptor antagonist.
Table 2. Type and dose of mineralocorticoid receptor antagonists prescribed to our patients, divided according to “early”  





Spironolactone 25.7% (n = 94) 25.3% (n = 81)
Spironolactone prescribed dose, mg/daya 29 ± 12 30 ± 17
Potassium canrenoate 38.3% (n = 140) 37.8% (n = 121)
Potassium canrenoate prescribed dose, mg/daya 36 ± 21 35 ± 23
Canrenone 36.0% (n = 131) 36.9% (n = 118)
Canrenone prescribed dose, mg/daya 35 ± 20 36 ± 19
Days to first ARA prescription, days (interquartile range) 0 (0–0) 59 (45–77)b
aFor patients not taking the drug daily, weekly dose was divided by seven; bmedian time before prescription time matching; the early and delayed 
groups had the same median and interquartile range after matching; ARA: aldosterone receptor antagonist.
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However, with ACE-I therapy now given routinely for 
congestive HF, the clinical importance of aldosterone had 
previously been overlooked because ACE-I therapy was 
widely believed to suppress aldosterone production effec-
tively by ‘upstream’ RAAS blockade. Increasingly, it is 
becoming evident that following an acute fall in aldoster-
one in response to administration of an ACE-I, the level of 
aldosterone rises again, and indeed returns to baseline in 
almost all patients, a phenomenon known as “aldosterone 
escape.”11,12,29–33 Even when an ACE-I is given in combina-
tion with an ARB, aldosterone levels remain uncon-
trolled.34,35 Additionally, there is evidence that aldosterone 
escape, in turn, might promote release of angiotensin II via 
a positive feedback loop that stimulates ACE in the vascu-
lature.36 This, and the progressive escape of aldosterone, 
are thought to contribute to “ACE-I resistance,” whereby 
the effect of ACE-I becomes blunted, and beneficial effects 
on mortality decrease over time.37,38 The results of our 
study allow us to postulate that the escape phenomenon 
occurs rapidly in patients who have had an episode of 
decompensated congestive HF. MRAs, in turn, are able to 
antagonize the deleterious effects of aldosterone, resulting 
in a beneficial effect, ultimately, on patient mortality.
ARAs utilized in the present study
While in the United States the most widely used MRA is 
represented by spironolactone, in Italy canrenone and 
potassium canrenoate are also used.
Potassium canrenoate is a competitive non-selective 
inhibitor of aldosterone receptor; its pharmacologic activity 
is due to a rapid conversion to canrenone, which is the active 
metabolite of potassium canrenoate and spironolactone.39 
Potassium canrenoate is rapidly and completely absorbed 
from the gastrointestinal tract and bypasses the liver 
unchanged. Canrenone and canrenoate are in enzymatic 
equilibrium in vivo, in which canrenoate represents the 
derived γ-hydroxycarboxylic acid.40 The bioavailability and 
water solubility of potassium canrenoate and canrenone are 
greater than those of spironolactone; therefore the number 
of active metabolites of the latter is considerably greater.40
In Italy eplerenone, a selective aldosterone receptor 
blocker, is not commercially available. All of the aldoster-
one inhibitors used in the present study are, in consequence, 
not selective.
In Italy, overall, MRAs are little used: In 2011 the mean 
number of doses of MRAs consumed daily by 1000 inhab-
itants was 3.5, a very small quantity compared with 88.5 
doses of ACE-Is, 56.3 of calcium channel blockers, 53.2 of 
ARBs, 38.5 of beta adrenergic blockers, 24.3 of loop diu-
retics, and 6.0 of thiazide diuretics.41 However, the present 
study is indicative of current clinical practices in a large 
Italian referral center. Our group, together with other refer-
ral Italian centers, is part of the AREA-in-CHF network, a 
research group that demonstrated in patients with HF posi-
tive effects of canrenone in preventing LV remodeling28 
and in improving myocardial mechano-energetic 
efficiency.42
Figure 1. Cumulative one-year mortality in patients with a first episode of decompensated heart failure among “early” and 
“delayed” users of mineralocorticoid receptor antagonists.
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Strengths and limitations of the study
The strengths of the present study are: first, the homogene-
ous cohort of patients; and second, the primary end-point of 
the study, represented by mortality from any cause. This is 
universally accepted as the strongest end-point in prognos-
tic studies.
Despite appropriate design and analyses, this study has 
several limitations. First, the study is prone to biases 
because of its observational nature. Although the bias that 
results from confounding by indication is minor, because 
all patients are MRA users, there are likely uncharacterized 
factors that may confound the timing of initiation. Some of 
them could be related to clinical practice and patient dis-
ease severity, which could obscure the possible benefit 
associated with early MRA initiation. Despite adjustment 
for a wide spectrum of characteristics, it is possible to have 
residual confounding in the comparisons. Second, survival 
bias in the comparison of early versus delayed MRA initia-
tion may affect the validity of the results. We controlled for 
this bias by matching the time of study entry between the 
two groups using prescription time distribution matching. 
However, due to matching, we could not study the effect in 
the first month. Third, our study is limited by the data and 
clinical practice during the study period, although patients 
were similar with regard to types of prescribed MRA and 
used dosages.
Conclusions
In patients suffering from HF, a delay of MRA initiation up 
to 30 days after discharge implies a significant increase in 
mortality compared with MRA initiation at discharge after 
a first episode of decompensated congestive HF. Subsequent 
studies, preferably randomized, should confirm these find-
ings. However, on the basis of the results of our study, it 
seems reasonable to suggest from a clinical point of view 
that patients with HF in whom there is a clear indication to 
use an MRA, should have the possibility of starting this 
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